Navigation Links
Asthma drug could help control or treat Alzheimer's disease
Date:3/25/2011

A drug used to treat asthma has been shown to help reduce the formation of amyloid beta, a peptide in the brain that is implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.

The researchers published their findings, "Pharmacologic Blockade of 5-Lipoxygenase Improves the Amyloidotic Phenotype of an AD Transgenic Mouse Model," in the American Journal of Pathology.

In previous studies, the Temple researchers discovered that 5-lipoxygenase, an enzyme long known to exist in the brain, controls the activation state of gamma secretase, another enzyme that is necessary and responsible for the final production of amyloid beta. When produced in excess, amyloid beta causes neuronal death and forms plaques in the brain. The amount of these amyloid plaques in the brain is used as a measurement of the severity of Alzheimer's.

In their current study, led by Domenico Pratic, an associate professor of pharmacology in Temple's School of Medicine, the researchers tested the drug Zileuton, an inhibitor of 5-lipoxygenase typically used to treat asthma, in a transgenic mouse model of Alzheimer's disease. At the end of the treatment they found that this drug, by blocking the 5-lipoxygenase, reduced gamma secretase's production of amyloid beta and the subsequent build up of amyloid plaques in the brain by more than 50 percent.

Pratic said that gamma secretase is present throughout the body and, despite its role in the development of amyloid plaques, plays a significant role in numerous important functions. Direct inhibitors of gamma secretase are known, he said, but blocking the enzyme completely may cause problems such as the development of cancer. Unlike classical gamma secretase inhibitors, Zileuton only modulates the protein expression levels, which keeps some of its vital functions in tact while blocking many of its bad effects, which in this case is the development of the amyloid plaques.

Pratic and his colleagues have begun working with researchers in Temple's Moulder Center for Drug Discovery Research to create more potent inhibitors that can target 5-lipoxygenase in the brain and increase the ability to reduce amyloid plaque formation and the development of Alzheimer's. Because Zileuton is already FDA approved, it is known that 5-lipoxygenase inhibition is an acceptable target that is not associated with overt toxicity and therefore not harmful to patients. The new drug derivative might be expected to advance to clinical trials relatively easily.

"This drug is already on the market and, most importantly, is already FDA-approved, so you don't need to go through an intense drug discovery process," said Pratic. "So we could quickly begin a clinical trial to determine if there is a new application for this drug against a disease where there is currently nothing."


'/>"/>

Contact: Preston M. Moretz
pmoretz@temple.edu
215-204-4380
Temple University
Source:Eurekalert

Related biology news :

1. Asthma tied to bacterial communities in the airway
2. Family mealtimes play a role in health of children with asthma
3. More research needed on diet and environmental influences on childhood asthma
4. Young people with asthma run a greater risk of developing caries
5. New asthma research breaks the mold
6. Discovery of taste receptors in the lungs could help people with asthma breathe easier
7. Possible alternate therapy for adults with poorly controlled asthma
8. Research and insights on severe asthma in children
9. Study points to key genetic driver of severe allergic asthma
10. Asthma and eczema sufferers have a lower risk of developing a cancer
11. Ultrafine particles in air pollution may heighten allergic inflammation in asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
Breaking Biology News(10 mins):
(Date:5/26/2017)... ... May 25, 2017 , ... LabRoots , the leading provider of scientific ... the world, is announcing a new textbook scholarship, the second scholarship in the LabRoots ... 17 years or older, pursuing a degree in one of the life sciences. The ...
(Date:5/24/2017)... BELLINGHAM, Washington, and WASHINGTON, DC, USA (PRWEB) , ... May 23, ... ... powerful driver of the economy as well as an enabler of life-saving medical and ... society for optics and photonics . They joined others in the scientific community today ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... A recent ... the most troublesome and difficult to control weed in 12 categories of broadleaf crops, ... Almost 200 weed scientists across the U.S. and Canada participated in the 2016 survey, ...
(Date:5/23/2017)... ... May 22, 2017 , ... A new Technology ... Diego, California, this August will feature high-level speakers on quantum devices, graphene electronic ... Optics and Photonics, the largest multidisciplinary optical sciences meeting in North America, will ...
Breaking Biology Technology: